Toronto-based psychedelic pharmaceutical company PharmaTher has partnered with Vitruvias Therapeutics to commercialize KETARX (racemic ketamine) products in the US.

Under the partnership, KETARX will be marketed in various dosage forms, including ready-to-administer applications, and will be promoted for FDA-approved uses, as well as off-label applications in mental health, neurological, and pain disorders. The companies plan to file an abbreviated new drug application (ANDA) in July and expect FDA approval in early 2024. Vitruvias will handle marketing, sales, and distribution activities, while PharmaTher will focus on regulatory aspects and manufacturing.